AML Categorization PCR Test in UAE | AED 1500 | DHA Licensed

Executive Summary & Core Metrics

Diagnostic Accuracy: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Temperature-controlled cold-chain transport (2–8 °C; never freeze).
Post‑Test Guidance: Complimentary telephonic clinical result interpretation with our genetics‑trained advisors.
Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731. Full compliance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning Use of ICT in Health Fields.

Test Overview & Methodology

This highly sensitive molecular test employs Real‑Time PCR (qPCR) and Whole Genome Sequencing (WGS) to identify and classify specific driver mutations (NPM1, FLT3‑ITD, CEBPA, and others) in acute myeloid leukemia (AML) cells. The panel provides a precise molecular fingerprint to guide targeted therapy and prognostic stratification under current DHA oncology protocols.

Feature	AML Categorization PCR	Traditional Karyotyping / FISH
Methodology	Real‑Time PCR (qPCR) + Whole Genome Sequencing (WGS)	Chromosome banding / FISH probes
Diagnostic Sensitivity	99.9% (mutation‑level resolution)	85–90% (structural anomalies only)
Turnaround Time	Mon samples by Wed, Thu samples by Sat	5–7 working days
Price (UAE)	AED 1500	Varies (often higher in private sector)
Sample Logistics	Hospital extraction only • Cold‑chain (2–8 °C; never freeze)	Requires fresh sample; strict handling

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) shares:

“Understanding your genetic profile is key to selecting the most effective treatment for AML. This PCR-based panel provides a detailed molecular picture that complements bone marrow findings, enabling your oncology team to tailor therapy with greater precision. Results should always be interpreted in the full context of your clinical presentation and recent labs.”

Medication & Safety Advisory

⚠ Important Medication Notice

Do not discontinue any prescribed treatment without your hematologist’s guidance. This test provides prognostic and therapeutic direction but does not replace a full clinical assessment.

Exclusion Criteria & Red Flags

Bone marrow sampling contraindications: Uncorrected severe thrombocytopenia (platelets <20,000/µL), active systemic infection, known bleeding disorder without haemostatic control, pregnancy (relative).
Seek emergency care if: Fever >38.3 °C, uncontrolled bleeding or bruising, severe bone or flank pain, signs of tumour lysis syndrome (muscle cramps, dark urine, confusion), or sudden shortness of breath.
Always inform your phlebotomist of any anticoagulants you are taking; blood samples must be handled in a refrigerated state and never frozen.

Patient FAQ & Clinical Guidance

1. What does the AML Categorization PCR Test detect?

This test identifies specific gene mutations (e.g., NPM1, FLT3‑ITD, CEBPA) in leukemia cells to classify AML subtypes and inform targeted therapy. It is performed on either a bone marrow aspirate or whole blood sample collected in a hospital setting.

2. How is the sample collected, and are home visits available?

Sample collection must take place in a hospital or accredited medical facility because a bone marrow aspirate or specialized blood draw is required. Home phlebotomy is not available for this test. The sample is then transported under strict cold‑chain conditions (2–8 °C; never freeze).

3. What is the turnaround time for results?

Samples received by 11 AM Monday are reported by Wednesday; samples received by 11 AM Thursday are reported by Saturday. This rapid schedule supports timely clinical decisions.

4. Is this test covered by insurance in the UAE?

Coverage varies by insurer. Our billing team can verify your direct billing eligibility via WhatsApp +971 54 548 8731. We support all major UAE insurance networks.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance

All clinical data and test results are protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DHA Facility License: 1143.

Clinical & Logistical Metadata

Test Name	AML Categorization PCR Test
Price (AED)	1500
Turnaround Time	Mon samples by Wed, Thu samples by Sat
Sample Type / Matrix	Bone marrow aspirate or whole blood (lavender-top EDTA) – Hospital extraction only
Methodology Used	Real-Time PCR (qPCR) + Whole Genome Sequencing (WGS)
ICD-10-CM Code	C92.00 (Acute myeloid leukemia, not having achieved remission)
LOINC Code	88214-7 (AML mutation panel)
DHA Facility License & Address	License: 1143 \| DNA Labs UAE \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE